Related Experiment Video
Updated: Feb 28, 2026

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
The 99th percentile of reference population for cTnI and cTnT assay: methodology, pathophysiology and clinical
Insights
Defining the 99th percentile upper reference limit (99th URL) for cardiac troponin (cTn) assays lacks standardized methods. This review highlights the need for international guidelines on selecting healthy populations and calculating 99th URL values for accurate clinical decisions.
Area of Science:
- Clinical Biochemistry
- Cardiology
- Medical Diagnostics
Background:
- International guidelines define clinically relevant cardiac troponin (cTn) increases above the 99th percentile upper reference limit (99th URL).
- Accurate cTn measurement is crucial for diagnosing myocardial infarction, with a 99th URL typically set at an imprecision of ≤10 CV%.
Purpose of the Study:
- To review methodological and pathophysiological factors influencing the evaluation and calculation of the 99th URL for cTn assays.
- To identify inconsistencies in current practices for defining and calculating the 99th URL for cTn.
Main Methods:
- Critical analysis of existing literature and guidelines concerning the 99th URL for cTn assays.
- Examination of factors affecting reference population selection and 99th URL calculation algorithms.
Main Results:
- No uniform procedures are followed for calculating the 99th URL for cTn assays.
- Lack of standardized guidelines from experts or regulatory bodies for defining healthy reference populations and calculating 99th URL values.
- Insufficient attention has been paid to the selection criteria for healthy reference populations and the mathematical algorithms used for 99th URL calculation.
Conclusions:
- There is a critical need for international recommendations on defining healthy reference populations and establishing standardized mathematical algorithms for calculating cTn 99th URL values.
- An expert consensus group should be formed to develop these essential guidelines for cTn assay manufacturers and clinical laboratories.
Abstract:
According to recent international guidelines, including the 2012 Third Universal Definiton of Myocardial Infarction by the Joint ESC/ACCF/AHA/WHF Task Force, an increase in cardiac troponin (cTn) levels over the 99th percentile upper reference limit (99th URL) should be considered clinically relevant, this cut-off being measured with an imprecision ≤10 CV%. In theory 99th URL values strongly depend not only on demographic and physiological variables (i.e. criteria for considering the reference population "healthy"), but also on the analytical performance of cTn methods and mathematical algorithms used for the calculation. The aim of the present article was therefore to review the methodological and pathophysiological factors affecting the evaluation and calculation of the 99th URL for cTn assay. The critical analysis made showed that no uniform procedure is followed, and nor have experts or regulatory bodies provided uniform guidelines for researchers or cTn assays manufacturers as an aid in "their quest to define normality". In particular, little attention has been paid to the way in which a healthy reference population is to be selected, or the criteria for calculating the 99th URL value for cTn assays, thus highlighting the need for international recommendations not only for demographic and physiological variables criteria for defining a healthy reference population, but also for calculating mathematical algorithms for establishing/calculating clinical decision values. An expert consensus group, comprising laboratory and clinical scientists, biomedical statisticians, industrial and regulatory representatives, should be responsible for drawing up these guidelines.
More Related Videos
09:23Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
Published on: December 13, 2017
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019